earnings. XXXX us for and market celebrating worth position was against morning, for quarter accelerated our and a executed thank our Orthofix. business. for Good across fourth Julie. you, strengthened you We year innovation everyone, joining Thank guidance, our the
invest our our our to pipeline fuel in advance and service ability and excellence technology continue We our most to growth. important portfolio our to people, surgeons to deliver and our support our need best differentiators,
portfolio We competitive in put profitably leadership initiatives, go-forward new that our growing organization long company taking team team and aligned our plan a profitable advantages significant a for our define advance growth strategy. cohesive, opportunities place to strategic this gross on advantage commercial Throughout and Orthofix's business. our capitalized with XXXX, term our of
grew our market [ growth rate in our X business and rate interbody more In XX% Spine], we thoracolumbar than tripled U.S. top growth including rate, the in the twice market the systems, fusion. in spinal cervical and implant fixation market growth fixation growth doubled
in the was enabling with more System patients more XXXX our included our any and a record-setting company generated record manufactured was support XD We technology strong Bone for year number placements. than with surgeons for life-changing Therapy Demand business. a of Growth and our and technology FLASH movies BGT. revenue, history Navigation year
build our and spine in status, Collectively, upon position to market market expander leading capabilities expand and we share orthopedics. continue our and best-in-class
sales. an and had for global excellent setting a both year, also business orthopedics record U.S. Our
position business of enables portfolio focused to market of are executing exceptionally an and are growing our most challenging We redefining [indiscernible] conditions new addressing of orthopedic category Under unique the innovative that optimizes internationally. unit the all of ages. gain our while we traction Orthofix in solutions leadership, meaningfully with patients the U.S.A. a our construction portfolio strategy in impact towards
and our patients. strengthened our to continue surgeon Across partners the commercial we their transform organization and with relationship business,
portfolios our leveraging new key an ] in products on enabling with each innovation relevering the product exceptional a of of of our market. to number our continue in technologies to and differentiate [ areas introductions strengths pace Additionally, across
and project our tackle strengthen we new and equip will us opportunities launched vital our our new that focus us teams market sharpened to most fuel to position, enable explore to Organizationally, essential within growth initiative, priorities XXXX. the
on focus and an our strategies innovating a commercial our With guide to to technologies, and experience dedicated disciplined organization customer arrival planning delivering execution efforts.
We our paved for position financial improved way have significantly and operating growth. the sustainable
of a in the we capacity, lower XXXX term positive $XX strides loan in new to increased financial with further million structure. second and the and optimize cash in made rates our competitor free XXXX, flow significant including negotiating strength, During extra improving half flexibility
that targets are financial profitable and long-term long-term growth, to started. set we reinforce our we commitment Finally, getting just
we believe preferences. will Looking products long-range an focus we forward. focus propel and our few that continued vital This to continue our fuel development [indiscernible] on includes plan innovation ahead, differentiated business in the to will growth and our of meet profitable initiatives
advanced and management enhancement ] atoms revenue flow. Our disciplined improved strategy leadership on cash through system financial strategic commercial and harness penetration comprehensive [ and to portfolio market efficiencies, operational technology to surgical drive that through free offerings, flow streams cash positive high-quality and planning for a sustainability excellence deeper growth emphasis sustain
our I'm path the our shareholders we and opportunities XXXX surgeons, beyond. their about set the have the energized for for and business to and exceptional value in patients deliver excited ourselves to and
the for quarter Now of on to fourth the XXXX. numbers
constant million performance further and providing sales balance represents fourth across mix X% evidence that basis year-over-year multiple X currency advantage markets. offer product of record all net across on a lines, complementary product of reflect Orthofix growth differentiated $XXX.X and a major Our above-market quarter
of far say that excellent and of positive free set We I had and flow expansion at $XX.X the are strong positive can leveraging confidently our to have advantages quarter of last in beyond. the business that momentum another margin original adjusted year. beginning we fundamentals EBITDA million, strategic we XXXX continue expectation exceeding our with cash
both XX%, strengthening driven of network. strong the market larger, and fixation distributors. our distributors grew with at significantly our and Reef spine increased addition More growth expanding and Interbody XX%, demand on was Revenue products grew market recently XX%. our over procedural relationship of to outperforming dedicated launched continued portfolio distributor of the specifically, our focus USA along grew more by top with lateral all portfolio selling WaveForm due our MIS and ALIF the the new
Growth in spine in within of number XX% XD Navigation increase XXXX, our our global the increase a been agreements. System by supported year-over-year FLASH has segment placement in including earnout
We to our are this platform partners. with differentiable long-standing surgeon leveraging create relationship
build advancement of solution OR. unique data-driven enabling in our investment, a and this intraoperative choice our portfolio seeking upon continued and generation hardware establish real-time foundation will us With the partner as in surgeons next for technology
our ventricular using drain cranial or received common a higher as EVD of external for navigation of FLASH EVD, FDA as end freehand product. neurosurgical the result procedure At standard the technique high catheter can quarter, fourth of the errors well a we rate infection. rate placement in clearance is but
FLASH EVD is these designed drawbacks. to address
a this footprint market clearance increased supports strategic the cranial presence not system. focus an the XD is for hospital at and our for us, Although
As our enabling confident its technology we strategy our ever significant more evolve,, in continues role portfolio. are than increasingly to in
planned, interbody lumbar introductions palatomists in ]. are a driving new and full technologies our solution force portfolio. varying continue and QX, Interbody, additional fusion This of proprietary surgeon products launches ALIF expand interbody Meridian an Reef product [ launch surgeons. to features of Lumbar address advanced design several New and portfolio in our our to product L surface preferences Lateral Beginning have doors the to we including open new
drive stickier and innovation of our ASP pull-through mix technology enable hospital in will talent, biologics us will we distributor precision benefit. hardware hardware, parallel, enhance comprehensive accounts with efficiency relationships relationships in that surgeons and and steady spinal attract which and expect with creating top solution In portfolio result predictability we incremental OR. enabling sales We and products a product lift to access comprehensive believe increase integrate to well to as navigation, the from our and as exclusive cadence
Therapies. Now to Growth Bone
market sales grew share own Even an in overall impressive as position continue we BGT Spine, to QX. net still the in X% #X
to with capitalizing points. conversions, our growth the than multiple strategy continue validating of take on from We of customer share more access new coming XX%
the in device BGT In the AccelStim addition, continuing market growth in market. outperform therapy growth to XX% bone drove investment channel the structure sales with structured
reminder, building early we the million, a represent the a the with become market market $XXX more in and than of in still to very of #X player. fracture position As goal an the our clear innings opportunity are
focused bone growth is of our most market-leading devices the business stimulation on BGT maximizing with Our position indication and portfolio the market. comprehensive in most
to AccelStim. on fracture new We in will a spine, channel continue representative focus the with penetration and cross-selling orthopedics sales add with and market established with drive market
our we year, engaging [indiscernible] by approval redefine through the anticipate we treatment to prescribed with patients expect this and for mobile AccelStim X.X, surgeons their the FDA app. experience recovery Later which
orthopedics XX%. Fitbone constant as as benefited strong record led combination the Our fixation net of was global a product by sales to compared growth currency our XX% sales products, delivered representing prior and in of record execution year. and GALAXY growth TrueLok orthopedics of family. QX, U.S. business in from the well Growth grew
of unique our product the the and which are innovative early in We given into U.S. incredible sales opportunities orthopedics presents expanding growth very market, lines. stages
[ we is limb preservation, and is market limb deformity frac limb that specifically category win, focus correction, includes Our complex where on management. can the of lengthening reconstruction, areas underserved redefining ] an
indicated Orthofix of of excited construction the Mark could condition tissue FDA solution and As and device bond is portfolio sailors. deformities transfers the the to of deep latest received for transport nonunions and addition tissue and wounds, registration all the a in address focused bonds. to for CE challenging or TrueLok clearance ulcer only ] we we that TrueLok bones TBT company Elevate external patients the limb family first [ have defects, nonhealing am flagship most correct which I in thoroughly FDA-cleared fixed unique or ] include system, [ is to growing, announce TrueLok TBT ages. of
complications sizable each opportunity $X.X the approximately American XXX,XXX to amputation a occur over as of Association, year According diabetic-related billion. of United representing a in Diabetes result States market
with amputation, patients have In a X%, to have will amputation. and for foot of care costs an mortality shown just addition, health over studies $XXX,XXX of [indiscernible] with ulcer rate carried X-year receive our diabetic that the related lifetime directly published
not offers to in limb as importantly, saving is potential TBT challenging be a solution The only most Elevate and TrueLok system cost select release market Thus, in to currently a limited life-saving the patient U.S.A. device, centers TrueLok Europe. but a and Elevate population.
that Fitbone introduction of Fitbone These customers. market available include product and share be the TrueLok we Orthopedics United number with XXXX and system, expect [indiscernible] fueled States a growth by new TBT existing additional will the in [indiscernible]. capture to new the in
XXXX. We these expect be of release market the in products half second to all of full in
Underpinning multiple market above sustained paths rates. breadth and Orthofix spine significant cross-portfolio are offering the strategies orthopedics business to our and opportunities. are of the depth business commercial provide The growth,
hardware, biologic advantage into We navigation spine, spine products our as of as to to spinal our BGT and cross-sell continue take opportunities introducing surgeon. accounts well BGT to
We orthopedics additional with and also stimulation biologic opportunities through products fracture our have our channel.
for to and and Overall, Orthofix several launch great our products on the delivering market-leading outcomes position efficiencies have and customers surgeon complex remain special limb in innovations a portfolio is therapies, bone biologics and orthopedic comprehensive markets, improve patients. meaningful success their trauma reconstruction leader growth market and product our such deformity We to capitalize a in in recent differentiated as correction.
world focus portfolio remain profitable and Additionally, clear about and strategy on compelling compelling but highly a for technology. Orthofix it's our is the growth clear the fully optimistic executing class opportunities results strategic our main enabling supported, ahead. I and pillars differentiated and delivering In [indiscernible] summary, is is spine
we deployment our that and have within profitable same product our of our where the technology confident or At also penetration are increased emphasis our platforms share drive capital will business can scale areas in on we growth and support transformation, we and less disciplined win. where deemphasizing areas time,
support platform well value particular, and on renewed three, innovate XXXX for the in term. to expand. our ensuring and spine our one, focus by to continue look number build to enabling positioned are our sharpening our two, commercial beyond, focus discipline plan we on Number procedure for to over we As create long further technology progress and we to deformity; number shareholders margin our
value. well momentum in strength our long-term continues confidence to growth of and while call positive TIV positioned on to deliver over portfolio, commitment and Our review which execution. innovation to financial now our our our win shareholder we believe our Julie to sustainable [ differentiated I guidance. results focused expanding full trends, the outline I'll to guidance share our year very and commercial strategy quarter disciplined are financial ] the that, and profitable fourth and our accelerate and increasing turn growth With drive XXXX reflects
